Neurocrine Biosci (NASDAQ:NBIX) stock price target increased to $62.00, released a report earlier today by Needham
- Updated: October 18, 2016
Stating a potential upside of 0.47%, Needham upped the price target of Neurocrine Biosci (NASDAQ:NBIX) to $62.00
On Tuesday October 04, 2016, Leerink Swann released a statement for Neurocrine Biosci (NASDAQ:NBIX) raised the target price from $0.00 to $70.00. At the time, this indicated a possible upside of 0.40%.
Yesterday Neurocrine Biosci (NASDAQ:NBIX) traded 4.23% higher at $42.30. The company’s 50-day moving average is $49.92 and its 200-day moving average is $47.80. The last stock close price is down -7.75% from the 200-day moving average, compared to the Standard & Poor's 500 Index which has decreased -0.01% over the same time period. 565,703 shares of NBIX traded hands, down from an average trading volume of 761,258
Recent Performance Chart
Neurocrine Biosci has 52 week low of $31.25 and a 52 week high of $58.46 and has a market capitalization of $0.
In addition to Needham reporting its stock price target, a total of 8 brokers have issued a report on the company. The average stock price target is $68.25 with 3 brokers rating the stock a strong buy, 6 brokers rating the stock a buy, 0 brokers rating the stock a hold, 0 brokers rating the stock a underperform, and finally 0 analysts rating the company a sell.
General Company Details For Neurocrine Biosci (NASDAQ:NBIX)
Neurocrine Biosciences, Inc. is engaged in the development of pharmaceutical products focused on neurological and endocrine-based diseases and disorders. The Company's two lead late-stage clinical programs are Elagolix, a gonadotropin-releasing hormone (GnRH) antagonist for women's health that is partnered with AbbVie Inc. (AbbVie), and NBI-98854 (valbenazine), a vesicular monoamine transporter 2 (VMAT2) inhibitor for the treatment of movement disorders. The Company focuses on developing NBI-640756 against Essential tremor. Its research and development focuses on addressing diseases and disorders of the central nervous and endocrine systems, which include therapeutic categories ranging from hypothalamic-pituitary-adrenal (HPA) disorders to stress-related disorders and neurological/neuropsychiatric diseases. Its Corticotropin-Releasing Factor (CRF) is a hypothalamic hormone released directly into the hypophyseal portal vasculature.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with MarketBeat.com's FREE daily email newsletter.